|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Homology-mediated end joining-based targeted integration using CRISPR/Cas9显示文摘 | Yao, Xuan Wang, Xing Hu, Xinde Liu, Zhen Liu, Junlai Zhou, Haibo Shen, Xiaowen Wei, Yu Huang, Zijian Ying, Wenqin Wang, Yan Nie, Yan-Hong Zhang, Chen-Chen Li, Sanlan Cheng, Leping Wang, Qifang Wu, Yan Huang, Pengyu Sun, Qiang Shi, Linyu Yang, Hui | 2017 | Cell Research2017，27，6： | 28 |
| 2 | SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors显示文摘Muta nt isocitrate dehydrog en ase 1(mlDH1)drives tumorigenesis via produci ng on cometabolite R-2-hydroxyglutarate(R-2-HG)across various tumor types.However,mlDHl in hibitors appear only effective in hematological tumors.The therapeutic ben efit in solid tumors remains elusive,likely due to the complex tumor microenvironment.In this study,we discover that R-2-HG produced by IDH1-mutant tumor cells is preferentially imported into vascular endothelial cells and remodels mitochondrial respiration to promote tumor angiogenesis,conferring a therapeutic vulnerability in IDH1-mutant solid tumors.Mechanistically,SLC1 Alz a Na'-depe ndent glutamate tran sporter that is prefere ntially expressed in en dothelial cells,facilitates the in flux of R-2-HG from the tumor microenvironment into the endothelial cells as well as the intracellular trafficking of R-2-HG from cytoplasm to mitochondria.R-2-HG hijacks SLC1A1 to promote mitochondrial Na^(+)/Ca^(2+)exchange,which activates the mitochondrial respiratory chain and fuels vascular en dothelial cell migratio n in tumor an giogenesis.SLC1A1 deficiency in mice abolishes mlDHl-promoted tumor an giogenesis as well as the therapeutic benefit of mlDHl in hibitor in solid tumors.Moreover,we report that HH2301,a newly discovered mlDHl inhibitor,shows promising efficacy in treating IDH1-mutant cholangiocarcinoma in preclinical models.Together,we identify a new role of SLC1A1 as a gatekeeper of R-2-HG-mediated crosstalk between IDH1-mutant tumor cells and vascular en dothelial cells,and dem on strate the therapeutic potential of mlDHl in hibitors in treating IDH1-muta nt solid tumors via disrupting R-2-HG-promoted tumor angiogenesis. | Xiaomin Wang Ziqi Chen Jun Xu Shuai Tang Nan An Lei Jiang Yixiang Zhang Shaoying Zhang Qingli Zhang Yanyan Shen Shijie Chen Xiaojing Lan Ting Wang Linhui Zhai Siyuwei Cao Siqi Guo Yingluo Liu Aiwei Bi Yuehong Chen Xiameng Gai Yichen Duan Ying Zheng Yixian Fu Yize Li Liang Yuan Linjiang Tong Kun Mo Mingcheng Wang Shu-Hai Lin Minjia Tan Cheng Luo Yi Chen Jia Liu Qiansen Zhang Leping Li Min Huang | 2022 | Cell Research2022，32，7： | 2 |
| 3 | A Solar Radio Spectrometer at 5.2–7.6?GHz显示文摘 | Huirong Ji Qijun Fu Yuying Liu Congling Cheng Zhijun Chen Yihua Yan Leping Zheng Zongjun Ning Chengmin Tan Debang Lao Shuke Li Jiyong Gao Zhiqiang Wang Minhong Yu | 2003 | Solar Physics2003，，2： | 1 |
| 4 | Reprogramming Glial Cells into Functional Neurons for Neuro-regeneration:Challenges and Promise显示文摘The capacity for neurogenesis in the adult mammalian brain is extremely limited and highly restricted to a few regions,which greatly hampers neuronal regeneration and functional restoration after neuronal loss caused by injury or disease.Meanwhile,transplantation of exogenous neuronal stem cells into the brain encounters several serious issues including immune rejection and the risk of tumorigenesis.Recent discoveries of direct reprogramming of endogenous glial cells into functional neurons have provided new opportunities for adult neuro-regeneration.Here,we extensively review the experimental findings of the direct conversion of glial cells to neurons in vitro and in vivo and discuss the remaining issues and challenges related to the glial subtypes and the specificity and efficiency of direct cell-reprograming,as well as the influence of the microenvironment.Although in situ glial cell reprogramming offers great potential for neuronal repair in the injured or diseased brain,it still needs a large amount of research to pave the way to therapeutic application. | Fengchao Wang Leping Cheng Xiaohui Zhang | 2021 | Neuroscience Bulletin2021，37，11： | 1 |
| 5 | Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission显示文摘Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT.Methods: A total of 74 newly diagnosed pediatric T-ALL patients between January 1, 2012 and June 30, 2018 were enrolled in this retrospective study. Patients were stratified into the low-risk chemotherapy cohort (n = 16), HR chemotherapy cohort (n = 31), and HR transplant cohort (n = 27). Characteristics, survival outcomes, and prognostic factors of all patients were then analyzed.Results: Patient prognosis in the HR chemotherapy cohort was significantly worse than that in the low-risk chemotherapy cohort (5-year overall survival [OS]: 58.5%vs. 100%,P = 0.003;5-year event-free survival [EFS]: 54.1%vs. 83.4%,P = 0.010;5-year cumulative incidence of relapse [CIR]: 45.2%vs. 6.3%,P = 0.011). In HR patients, allo-HSCT improved the 5-year EFS and CIR compared to that of chemotherapy (5-year EFS: 80.1%vs. 54.1%,P = 0.041;5-year CIR: 11.6%vs. 45.2%,P = 0.006). The 5-year OS was higher in the HR transplant cohort than that in the HR chemotherapy cohort (81.0%vs. 58.5%,P = 0.084). Minimal residual disease re-emergence was an independent risk factor for 5-year OS, EFS, and CIR;age ≥10 years was an independent risk factor for OS and EFS;and high white blood cell count was an independent risk factor for EFS and CIR.Conclusion: Allo-HSCT, especially haplo-HSCT, could effectively reduce relapse of children with HR T-ALL in CR1. | Zhang Yongzhan Bai Lu Cheng Yifei Lu Aidong Wang Yu Wu Jun Zhang Xiaohui Zuo Yingxi Xu Lanping Jia Yueping Huang Xiaojun Zhang Leping | 2022 | Chinese Medical Journal2022，，8： | 1 |
| 6 | Tlx1/3 and Ptf1a Control the Expression of Distinct Sets of Transmitter and Peptide Receptor Genes in the Developing Dorsal Spinal Cord显示文摘 | Zhen Guo Congling Zhao Menggui Huang Tianwen Huang Mingran Fan Zhiqin Xie Ying Chen Xiaolin Zhao Guannan Xia Junlan Geng Leping Cheng | 2012 | Journal of Neuroscience2012，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员